Accenture and BioCelerate Join hands to Advance Biopharmaceutical Innovation
Accenture announced its collaboration with BioCelerate to Advance Biopharmaceutical Innovations through Increased Insights in Research & Development.
The R&D data sharing platform will be built on the Accenture Insights Platformwich will provides a portfolio of advanced analytics capabilities, and an integrated design, build, run environment, to enable the development of industry and function-specific analytics solutions. The platform will provide participating member companies the ability to assimilate, aggregate, and analyze de-identified preclinical and clinical information, enabling them to draw their respective conclusions from a large data set. The platform will be used initially to support BioCelerate’s first collaborative project, Toxicology & Background Control Data Sharing, to enhance product safety.
Accenture Life Sciences North America and Accelerated R&D Services Senior managing director, Kevin Julian said that the ability to collect and leverage large amounts of precompetitive information to create new insights in the R&D process is an important development in the preclinical research space. They are eager to collaborate with BioCelerate on this critical initiative to further enable the sharing of data to maximize the value of preclinical and clinical research and deliver better patient outcomes.
Dalvir Gill, Ph.D. CEO of TransCelerate BioPharma said that Accenture’s deep expertise in life sciences, digital, analytics, and clinical data-related services will be instrumental in delivering this new platform and builds on the multi-year relationship between Accenture and TransCelerate. All BioCelerate member companies recently signed a collaborative Data Sharing Agreement outlining the guidelines of the data that will be shared across companies. This, along with selecting Accenture to build and host the global data sharing platform, marks another significant milestone in advancing the industry. They are truly excited for the long-term strategic vision of this platform and envisage a future whereby drug developers can connect preclinical, clinical and other data types within the same data sharing platform.